Apollomics, Inc. (APLM) 股票分析

公司概述

Apollomics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of oncology therapies designed to harness the immune system and target specific molecular pathways to inhibit cancer growth. The company functions within the healthcare sector, specifically the biotechnology industry, positioning it as an entity focused on high-risk, high-reward research and development activities rather than established product sales. With a market capitalization of $31.88M, annual revenue of $6.93M, and an employee count of 13, the company maintains a very small operational footprint typical of early-stage biotech firms. These valuation and revenue figures indicate that the company is in an early development phase where capital efficiency is critical, and the limited workforce suggests a lean organizational structure focused on core scientific objectives rather than broad commercial expansion.

财务健康

The company reported revenue of $6.93M over the trailing twelve months, yet posted a net income of -$31,188,000 and an EBITDA of -$26,359,000, revealing a significant gap that highlights a cost structure dominated by research and development expenditures rather than operating leverage. The free cash flow stands at -$14,440,000, which indicates that the company is currently burning cash and lacks the internal financial flexibility to fund operations without external capital raises or strategic partnerships. Gross margin is reported at 100.0%, reflecting the nature of clinical-stage assets where revenue is derived from specific contracts or milestones rather than traditional product sales with cost of goods sold, while the operating margin of -124.8% and profit margin of 0.0% underscore the substantial overhead costs relative to current income streams. On the balance sheet, the company holds $2.10M in cash against $744,000 in debt, though the debt-to-equity ratio is listed as N/A due to the negative equity implied by the financial results. The current ratio is 0.97, indicating that the company's current liabilities slightly exceed its current assets, suggesting a tight short-term liquidity position that requires careful cash management. Return on Equity is -380.1% and Return on Assets is -72.3%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and creditors, a common characteristic of pre-revenue biotechnology companies but one that warrants monitoring as the company approaches commercial milestones.

估值评估

The trailing P/E ratio is N/A due to the lack of positive net income, while the forward P/E is -22.85, a figure that implies the market is pricing in future earnings expectations that do not yet exist given the current loss-making status. The price-to-book ratio is -3.73, indicating that the market valuation is negative relative to the book value, which typically occurs when intangible assets and development costs exceed the net asset value recorded on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 4.60 and an EV/EBITDA of -0.57 suggest that investors are valuing the company primarily on its potential and pipeline assets rather than current profitability or earnings power. The stock's 52-week high is $42.12 and the 52-week low is $3.66, meaning the current trading price sits significantly below the yearly peak, reflecting the volatility and risk premium associated with clinical-stage biopharmaceuticals. With a beta of 1.83, the stock exhibits high price volatility relative to the broader market, moving nearly twice as much as the overall index in response to sector-specific news or general market fluctuations.

Growth & Income

Revenue growth year-over-year is 380.8%, while earnings growth is N/A, indicating that the company is scaling its top line rapidly but has not yet achieved profitability to measure earnings expansion. Since the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, all available resources are being reinvested into growth initiatives, research, and development rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechs aiming to advance their oncology therapies through clinical trials before generating sustainable commercial revenue. The overall growth and income profile is characterized by explosive revenue expansion coupled with significant cash consumption and a complete absence of dividend income, presenting a high-risk, high-potential capital allocation scenario.